the present invention satisfies needs left unresolved by the prior art by providing a method for synthesizing a soluble cocrystal formed by acetylsalicylic acid and l - theanine which is readily administerable to individuals through a variety of media . embodiments of the present invention employ l - theanine , a rare amino acid . l - theanine is a water - soluble , white crystalline powder , having a chemical abstracts service ( cas ) registry number of 3081 - 61 - 6 and a gras classification ( gras notice number : grn 000209 ). l - theanine has the empirical formula c 7 h 14 n 2 o 3 , a molecular weight of 174 . 20 , and the systematic name of 2 - amino - 4 -( ethylcarbamoyl ) butyric acid . being 5 - n - ethyl glutamine , theanine differs from glutamine by the ch2 - ch3 ( ethyl ) group ( replacing hydrogen ). n - ethyl confers on theanine its active properties . embodiments of the present invention include cocrystals of acetylsalicylic acid with theanine ( 5 - n - ethyl - glutamine ). further , the theanine contained in compositions according to embodiments of the present invention may be of any of l - form , d - form , dl - form . embodiments of the present invention may include the amino acid scaffolds glutamine and / or glutamic acid . non - limiting examples of enantiomers utilized in embodiments according to the present invention may include a d - enantiomer of theanine , d - glu ( nhet )- oh , 2r enantiomer ; an l - enantiomer of theanine , l - glu ( nhet )- oh , 2r enantiomer ; a dl enantiomer of theanine , dl - glu ( nhet )- oh enantiomer ; a d - enantiomer of theanine , d - gln ( et )- oh , 2r enantiomer ; an l - enantiomer of theanine , l - gln ( et )- oh , 2r enantiomer ; and a dl - enantiomer of theanine , dl - gln ( et )- oh , 2r enantiomer . the purity percentages of the d - enantiomers of theanine , d - glu ( nhet )- oh , 2r enantiomer and d - gln ( et )- oh , 2r enantiomer ; the l enantiomers of theanine , l - glu ( nhet )- oh , 2r enantiomer and l - gln ( et )- oh , 2r enantiomer ; and the dl - enantiomers of theanine , dl - glu ( nhet )- oh , 2r enantiomer and dl - gln ( et )- oh , 2r enantiomer in compositions according to embodiments of the present invention is 99 +%; 99 +% 2r enantiomer . the d - enantiomer at 99 +%; 99 +% ee % ( 2r ) is where the first measure is the overall chemical purity ( hplc ) and where the second measure is ee % ( 2r ) known as the “ percent enantiomeric excess .” the % ee is the measure of chiral purity equal to [% r −% s /% r ]* 100 defined by the ratios of their diasteriomeric derivatives . purity percentages may range from 90 % to 99 . 99 % in any d or l configuration of any theanine or any enantiomer thereof . embodiments of the present invention may include cocrystal compositions of acetylsalicylic acid and alpha variants of l - theanine , acetylsalicylic acid and alpha variants of d - theanine , and acetylsalicylic acid and alpha variants of dl - theanine . non - limiting examples of alpha variants used in embodiments according to the present invention may include l - northeanine , d - northeanine , dl - northeanine , l - homotheanine , d - homotheanine , dl - homotheanine l - bishomotheanine , d - bishomotheanine , and dl - bishomotheanine , i . e ., the respective c − 1 , c + 1 , and c + 2 homologous analogues of theanine . according to embodiments of the present invention the l -, d -, dl - alpha amino acids of theanine and their side - chain carbon homologues ( nor , homo , and bishomologues ) may have a functional r - group , where r1 may contain linear , cyclic , or branched alkyl groups and derivatives thereof ; linear , cyclic , or branched alkenyl groups and derivatives thereof ; and aromatic radicals and derivatives thereof . in embodiments of the present invention , the aromatic radicals may be aryl radicals . according to the embodiments of the present invention the single enantiomers ( s and r ) and racemic forms ( s , r - mixture ) of the beta amino acids of theanine may have a functional r - group , where r1 may contain linear , cyclic , or branched alkyl groups and derivatives thereof ; linear , cyclic , or branched alkenyl groups and derivatives thereof ; and aromatic radicals and derivatives thereof . in embodiments of the present invention , the aromatic radicals may be aryl radicals . embodiments of the present invention may include cocrystal compositions of acetylsalicylic acid and the enantiomers , l - and d - isomers , d , l - racemic mixture , s - and r - isomers , s , r - racemic mixtures , all rotamers , tautomers , salt forms , and hydrates of the alpha and beta amino acids of theanine in which the n - substituted functional r1 - group [ c4 or gamma - ch2 - c ( o )— nr1 ] may contain linear , cyclic , or branched alkyl groups and derivatives thereof ; linear , cyclic , or branched alkenyl groups and derivatives thereof ; and aromatic radicals and derivatives thereof making up all the analogue forms of theanine . in embodiments of the present invention , the aromatic radicals may be aryl radicals . an aqueous solution is a solution in which water is the dissolving medium or solvent , and which is essentially free of colloidal solids . dissolved crystals form true solutions and are capable of passing through a semi - permeable membrane as in dialysis , whereas colloids are unable to pass through a semi - permeable membrane . the compositions according to embodiments of the present invention form a true solution when dissolved in water , are able to pass through a semi - permeable membrane , and can be used in dialysis . examples of aqueous solutions that may be used in embodiments of the present invention include pure water , and the following : d5w , d10w , d50 , d5 0 . 3 % ns , d5 0 . 45 % ns , 0 . 45 % ns , d5 0 . 9 % ns , 0 . 9 % ns , 3 % nacl , d5rl , lr , nahco 3 , and xylitol solutions . solutions formed by dissolving acetylsalicylic acid - theanine cocrystal compositions according to embodiments of the present invention in water do not contain colloidal particles , and hence , do not exhibit the strong tyndall effect characteristic of colloidal dispersions . it should be understood that the term “ suitable ,” as it is used herein , generally refers to the fact that the solution can be administered intravenously to humans , without causing unfavorable side effects . the effective amount of acetylsalicylic acid administered to a patient ( i . e ., the amount that will have a salutary effect with regards to a disease or condition being treated ) will be influenced by gender , age , weight , body fluid status , severity of the disease or condition being treated , liver enzyme function , and renal excretion of salicylate which , in turn , is dependent upon urine ph , and protein binding of salicylates , which is concentration - dependent . the term “ carbohydrate ,” as it is used herein , generally refers to simple organic compounds that are aldehydes or ketones substituted with multiple hydroxyl groups , of the general formula ( ch 2 o ) n , where n is any number of three or greater . monosaccharides , disaccharides , trisaccharides , oligosaccharides , polysaccharides , dipeptides , and combinations of these may be used with the acetylsalicylic acid — theanine cocrystal compositions according to embodiments of the present invention , in particular , with those cocrystals formed according to the steps applied in examples 1 - 8 below . compositions according to embodiments of the present invention may contain the trisaccharide theanderose ( g6 - α - glucosyl sucrose ), a substance found specifically in honey . non - limiting examples of other natural sugars that may be used in embodiments of the present invention include abequose , allose , allulose , altrose , apiose , arabinose , beet oligosaccharides , bifurcose , deoxyribose , dextrose ( d - glucose ), erlose , erythrose , erythrulose , fructose ( levulose ), fucose , fuculose , galactose , gentiobiose , gentiotriose , gentiotetraose , etc ., gulose , hamamelose , inulobiose , inulotriose , inulotetraose , isomaltose , isomaltotriose , isomaltotetraose , isomaltopentaose , isomaltulose ( palatinose ), kestose , kojibiose , lactose , lactulose , laminaribiose , lyxose , mannose , maltose , maltotriose , maltotetraose , etc ., maltulose , meletzitose , melibiose , methose , nigerose , nystose , panose , paratose , primeverose , psicose , raffinose , rhamnose , ribose , ribulose , rutinose , sorbinose , sorbose , soybean oligosaccharides , stachyose , sucrose , tagatose , talose , theanderose , threose , trehalose , turanose , xylobiose , xylotriose , etc ., xylose , or xylulose , all of which may be used with acetylsalicylic acid in compositions according to embodiments of the present invention . the carbohydrates used in embodiments of the present invention may be of their respective d - or l - configurations . in certain embodiments , non - limiting examples of sugar alcohols that may be used include allitol , arabitol , erythritol , galactitol , glycerol , glycol , iditol , inositol , isomalt , lactitol , maltotetraol , maltotriol , mannitol , ribitol , sorbitol , talitol , threitol , and xylitol . the sugar alcohols used in embodiments according to the present invention may be of their respective the d - or l - configurations . these sugar alcohols have the benefits of having low glycemic indices . mannitol , for example , has been used to treat increased intracranial pressure . the following crystalloids may be used in formulations according to embodiments of the present invention : d5w , d10w , d50 , d5 0 . 3 % ns , d5 0 . 45 % ns , 0 . 45 % ns , d5 0 . 9 % ns , 0 . 9 % ns , 3 % nacl , d5rl , lr , nahco 3 , and xylitol solutions . formulations according to embodiments of the present invention may be fully dissolved in an aqueous solution and administered via the parenteral route . the following infusion fluids may be used in formulations according to embodiments of the present invention : d5w , d10w , d50 , d5 0 . 3 % ns , d5 0 . 45 % ns , 0 . 45 % ns , d5 0 . 9 % ns , 0 . 9 % ns , 3 % nacl , d5rl , lr , nahco3 , and xylitol solutions . next , the present invention will be described in further detail by means of examples , without intending to limit the scope of the present invention to these examples alone . the following are exemplary formulations of water - soluble acetylsalicylic acid compositions in accordance with the present invention . a cocrystal product of the present invention was prepared by weighing 352 mg of acetylsalicylic acid and 340 mg of l - theanine , and transferring the solids to an agate mortar . the solids were wetted with 500 μl of methanol , and hand - ground with a pestle until a dried crystalline mass was obtained . this product was characterized using differential scanning calorimetry (“ dsc ;” see fig2 ), x - ray powder diffraction (“ xrpd ;” see fig3 ), fourier - transform infrared spectroscopy with attenuated total reflectance sampling (“ ftir - atr ;” see fig4 ), and raman spectroscopy with diffuse reflectance sampling (“ ram - dr ;” see fig5 ). in addition , 117 mg of the cocrystal product was found to dissolve in 13 ml of water , making the aqueous solubility approximately 9 mg / ml . the aqueous solution formed in example 1 was poured in an evaporating dish , and allowed to dry completely . the dsc thermogram of the solid product is reflected in fig2 , the xrpd pattern is reflected in fig3 , the ftir - atr spectrum is reflected in fig4 , and the ram - dr spectrum is reflected in fig5 . 1 . 721 g of acetylsalicylic acid and 1 . 667 g of l - theanine were weighed and transferred into a large glass mortar . the solids were wetted with 20 ml of methanol , and hand - ground with a pestle until a dried crystalline mass was obtained . the dsc thermogram of the solid product is reflected in fig2 , the xrpd pattern is reflected in fig3 , the ftir - atr spectrum is reflected in fig4 , and the ram - dr spectrum is reflected in fig5 . 752 mg of the cocrystal product was found to dissolve in 80 ml of water , making the aqueous solubility 9 . 4 mg / ml . aliquots of the aqueous solution were separately diluted in 1 : 1 v / v ratios with ( a ) ph 7 . 4 tromethamine buffer , ( b ) 0 . 9 % saline solution , ( c ) 7 . 5 % sodium bicarbonate solution , ( d ) 5 % dextrose for injection , and ( e ) 50 % dextrose for injection . the solutions were observed to remain physically unchanged over a six - day period , indicating compatibility of the cocrystal product with each of the infusion solutions . 435 mg of acetylsalicylic acid and 424 mg of l - theanine were weighed into a 200 ml round - bottomed flask , and dissolved in 100 ml of water . the resulting clear solution was then dried using rotatory evaporation until a dried crystalline mass was obtained . the dsc thermogram of this solid product is reflected in fig2 , the xrpd pattern is reflected in fig3 , the ftir - atr spectrum is reflected in fig4 , and the ram - dr spectrum is reflected in fig5 . 752 mg of the cocrystal product was found to dissolve in 80 ml of water , making the aqueous solubility 9 . 4 mg / ml . a cocrystal product of the present invention was prepared by weighing 353 mg of acetylsalicylic acid and 341 mg of d - theanine , and transferring the solids to an agate mortar . the solids were wetted with 500 μl of methanol , and hand ground with a pestle until a dried crystalline mass was obtained . representative photomicrographs of the cocrystal product are shown in fig6 this product was characterized using differential scanning calorimetry ( dsc ; see fig7 ), x - ray powder diffraction ( xrpd ; see fig8 ), fourier - transform infrared spectroscopy with attenuated total reflectance sampling ( ftir - atr ; see fig9 ), and raman spectroscopy with diffuse reflectance sampling ( ram - dr ; see fig1 ). in addition , 68 mg of the cocrystal product was found to dissolve in 7 . 5 ml of water , making the aqueous solubility approximately 9 mg / ml . 363 mg of acetylsalicylic acid and 354 mg of d - theanine were weighed into a 150 ml beaker , and dissolved in 100 ml of water . the resulting clear solution was then dried using rotatory evaporation until a dried crystalline mass was obtained . the dsc thermogram of this solid product is reflected in fig7 , the xrpd pattern is reflected in fig8 , the ftir - atr spectrum is reflected in fig9 , and the ram - dr spectrum is reflected in fig1 . a cocrystal product of the present invention was prepared by weighing 368 mg of acetylsalicylic acid , 179 mg of l - theanine , and 178 mg of d - theanine , and transferring the solids to an agate mortar . the solids were wetted with 500 μl of methanol , and hand ground with a pestle until a dried crystalline mass was obtained . representative photomicrographs of the cocrystal product are shown in fig1 . this product was characterized using differential scanning calorimetry ( dsc ; see fig1 ), x - ray powder diffraction ( xrpd ; see fig1 ), fourier - transform infrared spectroscopy with attenuated total reflectance sampling ( ftir - atr ; see fig1 ), and raman spectroscopy with diffuse reflectance sampling ( ram - dr ; see fig1 ). in addition , 67 mg of the cocrystal product was found to dissolve in 9 . 5 ml of water , making the aqueous solubility approximately 7 mg / ml . 358 mg of acetylsalicylic acid , 175 mg of l - theanine , and 174 mg of d - theanine were weighed into a 150 - ml beaker , and dissolved in 100 ml of water . the resulting clear solution was then dried using rotatory evaporation until a dried crystalline mass was obtained . the dsc thermogram of this solid product is reflected in fig1 , the xrpd pattern is reflected in fig1 , the ftir - atr spectrum is reflected in fig1 , and the ram - dr spectrum is reflected in fig1 . the tyndall effect is observed when particles of a solid are dispersed in water but not dissolved . such an effect is strongly observed in dispersions of bayer aspirin , disprin , and aspro clear . no such strong effect is observed in water , or when cocrystal compositions according to embodiments of the present invention are dissolved in water . colloids are particles which range in size from 1 - 1000 nm , and a tyndall effect is created when a laser beam is scattered by its passage through a colloidal dispersion of non - dissolved particles . for such dispersions , the illumination of a visible path through the colloidal dispersion is observable . a true solution , such as water or a composition according to embodiments of the present invention dissolved in water , does not contain colloidal particles , and hence does not exhibit a strong tyndall effect characteristic of colloidal dispersions . these findings , detailed below , as well as the preceding examples , demonstrate that compositions according to embodiments of the present invention dissolve to form true solutions in water , and do not merely disperse to form a colloidal dispersion . 300 mg of the aspirin :( l )- theanine cocrystal product was dissolved in 150 ml of water in one beaker and a 325 mg tablet of disprin was dispersed in 150 ml of water in another beaker . a 514 nm laser beam was first passed through the aspirin :( l )- theanine cocrystal solution and then through the disprin dispersion . a strong tyndall effect was observed in the aqueous dispersion of disprin , but was not observed with the composition according to the present invention dissolved in water . an investigation regarding the degree of insoluble substance remaining after performance of the tyndall effect experiment was carried out . the dispersions in the beakers were stirred to collect any undissolved solid in the center . an accumulation of undissolved solid formed at the bottom of the disprin beaker , but not in the beaker containing aspirin ( l )- theanine cocrystal product which displayed a crystal - clear solution . 300 mg of the aspirin :( l )- theanine cocrystal product was dissolved in 150 ml of water in one beaker and a 300 mg tablet of aspro clear was dispersed in 150m1 water in another beaker . a 514 nm laser beam was first passed through the aspirin :( l )- theanine cocrystal solution and then through the aspro clear dispersion . a strong tyndall effect was observed in the aqueous dispersion of aspro clear , but was not observed with the composition according to the present invention dissolved in water . an investigation regarding the degree of insoluble substance remaining after performance of the tyndall effect experiment was carried out . the dispersions in the beakers were stirred to collect any undissolved solid in the center . an accumulation of undissolved solid formed at the bottom of the aspro clear beaker , but not in the beaker containing aspirin : ( l )- theanine cocrystal product which exhibited a crystal - clear solution . 300 mg of the aspirin :( l )- theanine cocrystal product was dissolved in 150 ml of water in one beaker and a 325 mg tablet of bayer aspirin was dispersed in 150 ml of water in another beaker . a 514 nm laser beam was first passed through the aspirin :( l )- theanine cocrystal solution and then through the bayer aspirin dispersion . a strong tyndall effect was observed in the aqueous dispersion of bayer aspirin , but was not observed with the composition according to the present invention dissolved in water . an investigation regarding the degree of insoluble substance remaining after performance of the tyndall effect experiment was carried out . the dispersions in the beakers were stirred to collect any undissolved solid in the center . an accumulation of undissolved solid formed at the bottom of the bayer aspirin beaker , but not in the beaker containing aspirin :( l )- theanine cocrystal product which displayed a crystal - clear solution . 300 mg of the aspirin :( l )- theanine cocrystal product was dissolved in 150 ml of water in one beaker and 150 ml of water alone was place in another beaker . a 514 nm laser beam was first passed through the aspirin : ( l )- theanine cocrystal solution and then through the water . a strong tyndall effect was not observed with water , nor was it observed with the composition according to the present invention dissolved in water . both water and the aspirin :( l )- theanine cocrystal product exhibited crystal - clear solutions and were indistinguishable from one other . an investigation regarding the degree of insoluble substance remaining after performance of the tyndall effect experiment was carried out . the dispersion in the beaker containing the dissolved aspirin :( l )- theanine cocrystal product was stirred to collect any undissolved solid in the center . no undissolved solids were observed at the bottom of the beaker with the aspirin :( l )- theanine cocrystal product . both water and the aspirin :( l )- theanine cocrystal product produced crystal - clear solutions and were indistinguishable from one other . 300 mg of the aspirin :( d )- theanine cocrystal product was dissolved in 150 ml of water in one beaker and a 325 mg tablet of disprin was dispersed in 150 ml of water in another beaker . a 514 nm laser beam was first passed through the aspirin :( d )- theanine cocrystal solution and then through the disprin dispersion . a strong tyndall effect was observed in the aqueous dispersion of disprin , but was not observed with the composition according to the present invention dissolved in water . an investigation regarding the degree of insoluble substance remaining after performance of the tyndall effect experiment was carried out . the dispersions in the beakers were stirred to collect any undissolved solid in the center . an accumulation of undissolved solid formed at the bottom of the disprin beaker , but not in the beaker containing aspirin ( d )- theanine cocrystal product which displayed a crystal - clear solution . 300 mg of the aspirin :( d )- theanine cocrystal product was dissolved in 150 ml of water in one beaker and a 300 mg tablet of aspro clear was dispersed in 150 ml water in another beaker . a 514 nm laser beam was first passed through the aspirin :( d )- theanine cocrystal solution and then through the aspro clear dispersion . a strong tyndall effect was observed in the aqueous dispersion of aspro clear , but was not observed with the composition according to the present invention dissolved in water . an investigation regarding the degree of insoluble substance remaining after performance of the tyndall effect experiment was carried out . the dispersions in the beakers were stirred to collect any undissolved solid in the center . an accumulation of undissolved solid formed at the bottom of the aspro clear beaker , but not in the beaker containing aspirin :( d )- theanine cocrystal product which displayed a crystal - clear solution . 300 mg of the aspirin :( d )- theanine cocrystal product was dissolved in 150 ml of water in one beaker and a 325 mg tablet of bayer aspirin was dispersed in 150 ml of water in another beaker . a 514 nm laser beam was first passed through the aspirin :( d )- theanine cocrystal solution and then through the bayer aspirin dispersion . a strong tyndall effect was observed in the aqueous dispersion of bayer aspirin , but was not observed with the composition according to the present invention dissolved in water . an investigation regarding the degree of insoluble substance remaining after performance of the tyndall effect experiment was carried out . the dispersions in the beakers were stirred to collect any undissolved solid in the center . an accumulation of undissolved solid formed at the bottom of the bayer aspirin beaker , but not in the beaker containing aspirin ( d )- theanine cocrystal product which displayed a crystal - clear solution . 300 mg of the aspirin :( d )- theanine cocrystal product was dissolved in 150 ml of water in one beaker and 150 ml of water alone was placed in another beaker . a 514 nm laser beam was first passed through the aspirin :( d )- theanine cocrystal solution and then through the water . a strong tyndall effect was not observed with water , nor was it observed with the composition according to the present invention dissolved in water . both water and the aspirin :( d )- theanine cocrystal product produced crystal - clear solutions and were indistinguishable from one other . an investigation regarding the degree of insoluble substance remaining after performance of the tyndall effect experiment was carried out . the dispersion in the beaker containing the dissolved aspirin : ( d )- theanine cocrystal product was stirred to collect any undissolved solid in the center . no undissolved solids were observed at the bottom of the beaker with the aspirin :( d )- theanine cocrystal product . both water and the aspirin :( d ) theanine cocrystal product produced crystal - clear solutions and were indistinguishable from one other . 300 mg of the aspirin :( dl )- theanine cocrystal product was dissolved in 150 ml of water in one beaker and a 325 mg tablet of disprin was dispersed in 150 ml of water in another beaker . a 514 nm laser beam was first passed through the aspirin :( dl )- theanine cocrystal solution and then through the disprin dispersion . a strong tyndall effect was observed in the aqueous dispersion of disprin , but was not observed with the composition according to the present invention dissolved in water . an investigation regarding the degree of insoluble substance remaining after performance of the tyndall effect experiment was carried out . the dispersions in the beakers were stirred to collect any undissolved solid in the center . an accumulation of undissolved solid formed at the bottom of the disprin beaker , but not in the beaker containing aspirin :( dl )- theanine cocrystal product which displayed a crystal - clear solution . 300 mg of the aspirin :( dl )- theanine cocrystal product was dissolved in 150 ml of water in one beaker and a 300 mg tablet of aspro clear was dispersed in 150 ml water in another beaker . a 514 nm laser beam was first passed through the aspirin :( dl )- theanine cocrystal solution and then through the aspro clear dispersion . a strong tyndall effect was observed in the aqueous dispersion of aspro clear , but was not observed with the composition according to the present invention dissolved in water . an investigation regarding the degree of insoluble substance remaining after performance of the tyndall effect experiment was carried out . the dispersions in the beakers were stirred to collect any undissolved solid in the center . an accumulation of undissolved solid formed at the bottom of the aspro clear beaker , but not in the beaker containing aspirin ( dl )- theanine cocrystal product which displayed a crystal - clear solution . 300 mg of the aspirin :( dl )- theanine cocrystal product was dissolved in 150 ml of water in one beaker and a 325 mg tablet of bayer aspirin was dispersed in 150 ml of water in another beaker . a 514 nm laser beam was first passed through the aspirin :( dl )- theanine cocrystal solution and then through the bayer aspirin dispersion . a strong tyndall effect was observed in the aqueous dispersion of bayer aspirin , but was not observed with the composition according to the present invention dissolved in water . an investigation regarding the degree of insoluble substance remaining after performance of the tyndall effect experiment was carried out . the dispersions in the beakers were stirred to collect any undissolved solid in the center . an accumulation of undissolved solid formed at the bottom of the bayer aspirin beaker , but not in the beaker containing aspirin ( dl )- theanine cocrystal product which displayed a crystal - clear solution . 300 mg of the aspirin :( dl )- theanine cocrystal product was dissolved in 150 ml of water in one beaker and 150 ml of water alone was placed in another beaker . a 514 nm laser beam was first passed through the aspirin :( dl )- theanine cocrystal solution and then through the water . a strong tyndall effect was not observed with water , nor was it observed with the composition according to the present invention dissolved in water . both water and the aspirin :( dl )- theanine cocrystal product produced crystal - clear solutions and were indistinguishable from one other . an investigation regarding the degree of insoluble substance remaining after performance of the tyndall effect experiment was carried out . the dispersion in the beaker containing the dissolved aspirin :( dl )- theanine cocrystal product was stirred to collect any undissolved solid in the center . no undissolved solids were observed at the bottom of the beaker with the aspirin :( dl )- theanine cocrystal product . both water and the aspirin :( dl )- theanine cocrystal product produced crystal - clear solutions and were indistinguishable from one other . derivatives prepared using compositions according to embodiments of the present invention can be administered via intravenous , intramuscular , intradermal , subcutaneous , intraperitoneal , intraarticular , sublingual , subconjunctival , and intravitreal routes , or in the form of eye drops , orally , topically , rectally , via nasal spray , inhalation , and nanoparticle delivery systems . the pharmaceutical compositions according to embodiments of the present invention may be prepared as oral solids ( tablets , oral disintegrating tablets , effervescent tablets , capsules ), oral liquids , hard or soft gelatin capsules , quick dissolve , controlled released , modified released , syrups , suspensions , granules , wafers ( films ), pellets , lozenges , powders , chewables , suppositories , ointments , solutions , parenteral / injectable powders or granules that are pre - mixed or reconstituted , lotions , gels , creams , foams , and nanoemulsions . the pharmaceutical compositions according to embodiments of the present invention may be combined with lipooxygenase inhibitor agents , natural lipooxygenase inhibitors , anti - hypertensive agents , anti - hyperlipidemic agents , anti - hypertensive / anti - hyperlipidemic agents , anti - triglyceride agents , anti - migraine agents , blood modifier agents , especially thrombolytic agents and platelet aggregation inhibitor agents , anti - neoplastic agents , anti - psychotic agents , anti - anxiety agents , anti - convulsant agents , anti - parkinsonian agents , anti - diabetic agents , anti - inflammatory agents such as corticosteroids , anti - pyretic agents excluding nsaids ( nsaids when combined with aspirin , negate the effects of aspirin ), anti - rheumatic agents excluding nsaids , agents for treatment of symptoms associated with premenstrual syndrome excluding nsaids , anti - arrhythmic agents , digitalis glycosides , anti - anginal agents ( nitrates , anti - platelet agents , beta blockers , calcium channel blockers and ranolazine ), analgesic agents , musculoskeletal relaxants , anti - infective agents especially antibiotics , parenteral nutritional agents , magnesium , co - enzyme q 10 , sarcosine , amino acids , vitamins ( except vitamin k ), and agents used to treat diseases associated with excess amounts of glutamate such as , but not limited to amyotrophic lateral sclerosis , cerebrovascular dementia , and with brain injuries , as occurs with non - hemorrhagic strokes or physical injuries . the pharmaceutical compositions of the invention with theanine are not limited to these agents . intravenous formulations according to embodiments of the present invention include new compounds that are combined lipooxygenase / cyclooxygenase inhibitors for treatment of , among other things , myocardial ischemia , myocardial infarction , cerebral ischemia , stroke , atherosclerosis , retinal ischemia , rheumatoid arthritis , osteoarthritis , inflammatory bowel disease , and certain types of cancers . embodiments of the present invention have other potential clinical applications including , but not limited to the following : cardiovascular ( treatment of acute coronary syndrome , treatment of acute myocardial infarction , adjunctive therapy in revascularization procedures : percutaneous transluminal coronary angioplasty , coronary artery bypass grafts , carotid enarterectomy , and stent implantation ); neurologic ( treatment of acute ischemic stroke ); dysphagia ( from any etiology ); rheumatologic ( rheumatoid arthritis , ankylosing spondylitis , spondyloarthropathies , pleurisy and arthritis of systemic lupus erythematous , psoriatic arthritis , fibromyalgia , reiter &# 39 ; s syndrome , osteoarthritis , lyme arthritis and gonorrhea arthritis ); anti - inflammatory ( epididymitis , bornholm &# 39 ; s disease ( coxsackie myocarditis ), acute pericarditis , dressler &# 39 ; s syndrome , acute rheumatic fever , ross river fever ); pain management ( marine envenomations such as from jellyfish , sea urchins , star fish , portuguese man - of - wars , fire corals , sea anemones , lionfish , stonefish , and stingrays ; osgood - schlatter disease , idiopathic ( primary ) erythromelalgia , burns , acute renal colic , trigeminal neuralgia , bone pain ( osteoid osteomas , pagets disease , sickle cell anemia ), spinal stenosis , metastatic disease , intractable headaches , radiculopathies , and other chronic pain syndromes ; as an adjuvant to morphine for patient - controlled analgesia ( pca ); ophthalmologic ( retinal ischemia and retinal occlusion ); emergent use ( in ambulances , hospital emergency rooms and critical care units , doctors &# 39 ; offices , air travel , in the wilderness , etc . ); with intubated patients and patients with severely compromised bowel function , excluding crohn &# 39 ; s disease and ulcerative colitis ; as an anti - pyretic for high grade temperatures , excluding malignant hyperthermia ; for prevention of post - anesthetic shivering ; for closure of patent ductus arteriosus ; for familial cylindromatosis ; for inhibition of angiogenesis ; for inhibition of niacin flushing ; as an adjuvant to thrombolytic therapy for the treatment of frostbite ; the treatment of rare diseases ( including kawasaki disease , riedel thyroiditis , adult - onset still &# 39 ; s disease , kikuchi - fujimoto disease , focal myositis , weber - christian disease , and adhesive arachnoiditis ); substantial protection against hepatotoxic effects from drugs , alcohol , herbs , toxins , chemicals , obesity - related liver disease and radiation - induced liver disease ; and for providing anti - hiv effects . embodiments of the present invention may be employed to provide substantial protection against a wide variety of medical conditions , including but not limited to , the hepatotoxic effects from tylenol , statins , antiretrovirals , alcohol , and other drugs , toxins , herbs , and chemicals that are capable of inducing hepatoxicity ; obesity - related liver disease ; and radiation - induced liver disease . cocrystals according to embodiments of the present invention may be used to improve one or more physical properties , such as solubility , stability , and dissolution rate , of the active pharmaceutical ingredient of a selected treatment or prevention . while specific embodiments of the invention have been shown and described in detail to illustrate the application of the principles of the invention , it will be understood that the invention may be embodied otherwise without departing from such principles .
a method of reducing hepatocellular damage in a subject using a water - soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer .